logo
Plus   Neg
Share
Email

Lilly Announces New Leadership In Oncology R&D

Eli Lilly and Co. (LLY) announced new leadership in oncology R&D, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019.

The company noted that the new organization, named Loxo Oncology at Lilly, will be led jointly by Josh Bilenker, Jacob Van Naarden, and Nisha Nanda, and will report into Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories.

Lilly also announced that David Hyman will join the leadership team as chief medical officer of the new organization, beginning in January 2020. Hyman currently serves as chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center.

The company noted that the new organization will also pursue acquisition and in-licensing opportunities. Development of several early clinical-stage programs will be wound down and terminated.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>